Rein Therapeutics Inc., a biopharmaceutical company focusing on orphan pulmonary and fibrosis indications, reported a net loss of $5.5 million for the first quarter ended March 31, 2025, a decrease from the $7.1 million net loss experienced in the same period in 2024. This translated to a basic and diluted net loss per share of $0.25, compared to $0.86 in the prior year. The company's cash and cash equivalents stood at $7.4 million as of March 31, 2025, down from $12.9 million at the end of 2024. However, Rein has extended its cash runway through September 2025 following warrant transactions and a private placement that raised approximately $5.28 million in April 2025. Research and Development expenses decreased to $3.1 million from $3.5 million in the previous year, largely due to a temporary delay in further clinical development of LTI-01. General and Administrative expenses also saw a reduction to $2.5 million from $3.7 million, attributed primarily to decreased professional fees and employee-related costs. Rein Therapeutics has also initiated the RENEW Phase 2 trial for LTI-03 in idiopathic pulmonary fibrosis, with interim data expected in the first half of 2026, and has had two abstracts accepted to the American Thoracic Society 2025 International Conference.